Study guide
9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacist Licensure & Reciprocity
1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement
2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios
2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles
3 Chapter 3: Prescriptive Authority & Practitioner Categories
3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members
4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)
4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR
5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing
6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling
6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)
7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose
7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)
8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping
8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)
9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety
9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment
12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy
12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols
9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
Key Takeaways Explain This Topic AI
Once a prescription drug has been dispensed and handed to the patient, it generally cannot be returned to stock and redispensed, because broken chain-of-custody and unknown storage conditions create adulteration and misbranding risk.
Controlled substances may never be redispensed after dispensing—federal law prohibits transferring a controlled substance to anyone other than the person for whom it was prescribed; returned or abandoned controlled substances must be destroyed via a DEA-authorized collector or reverse distributor.
Restocking (return-to-stock) is permissible only when the filled prescription was never picked up or delivered to the patient; the pharmacy must reverse the billing and document the reason within the state-required window.
NABP's position is that return-and-reuse programs are contrary to most state practice acts; where allowed, they require board approval and tamper-evident, unit-of-use packaging in the dispensing pharmacy's original container.
State prescription drug donation/repository programs may redispense qualifying donated drugs to low-income patients, but controlled substances are universally prohibited from donation.
Last updated: July 2026
9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
MPJE Core Concept: Whether a dispensed drug can be taken back and given to another patient is one of the most tested "return and reuse" scenarios. The default federal and state rule is no —once a drug leaves the pharmacy in the patient's hands, broken chain-of-custody and unknown storage make it suspect for adulteration and misbranding. Controlled substances are categorically barred from redispensing. Narrow exceptions (restocking never-dispensed prescriptions, sealed unit-dose returns from licensed facilities, and state donation/repository programs) exist but require strict conditions.
1. The Default Rule: No Redispensing of Patient-Returned Drugs
After a prescription drug has been dispensed and handed to the patient (or the patient's agent) , it has left the pharmacy's control. The pharmacy cannot verify that the drug was stored at the proper temperature, was not tampered with, was not contaminated, and was not swapped. Reintroducing such a product to stock for redispensing risks dispensing an adulterated (degraded or contaminated) or misbranded (not in its original labeling) drug under the FD&C Act. Accordingly, most state pharmacy practice acts prohibit accepting a returned dispensed drug for redispensing , and NABP's position paper on return-and-reuse programs states that such programs are contrary to most, if not all, state practice acts unless expressly authorized by the board of pharmacy.
Practical consequence: many community pharmacies adopt a no-return policy on dispensed prescription drugs (other than internally handled recall or error corrections) precisely because lawful reuse is so narrow.
2. Controlled Substances: Absolute Federal Prohibition
For controlled substances the federal rule is stricter. A controlled substance dispensed to a patient cannot be redispensed to anyone else. Federal law prohibits transferring a controlled substance to any person other than the one for whom it was prescribed; once dispensed, the controlled substance is the patient's property. Therefore:
A returned controlled substance may not re-enter pharmacy inventory.
Unwanted or abandoned controlled substances must be destroyed —typically surrendered to a DEA-authorized collector (a pharmacy registered with DEA as a collector that maintains a secure take-back receptacle) or transferred to a DEA-registered reverse distributor for destruction.
Drugs accepted at a take-back receptacle are collected for disposal only ; they may not be redispensed or returned for cash or credit.
In long-term-care or hospital settings, abandoned patient controlled substances (for example, a deceased patient's medications that cannot be returned) must be disposed of under DEA guidance, often with law-enforcement or DEA Diversion Field Office involvement.
Exam trap: A patient asks to "return" an unused Schedule II opioid for credit or redispensing. The correct pharmacist action is to refuse redispensing and credit, and to offer disposal through a DEA-authorized collector or reverse distributor—never to return the controlled substance to stock.
3. Restocking (Return-to-Stock) of Never-Dispensed Prescriptions
This is different from a patient return. If a prescription was filled but never picked up or delivered to the patient (the drug never left the pharmacy), the pharmacy may generally return the product to stock , provided:
- The drug remained under the pharmacy's control in appropriate storage;
- The product's integrity and expiration dating are intact;
The pharmacy reverses the prescription billing (and any third-party claim) within the payer- or state-required window, so the drug is not double-billed;
The return-to-stock and the reason are documented , and any state limit on the number of times a single prescription may be filled or picked up is respected.
Some states limit return-to-stock to once per prescription or impose a deadline (for example, 14 days) after which the filled-but-unclaimed prescription must be returned to stock or destroyed. The key MPJE distinction: restocking concerns a drug the patient never received; reuse or redispensing concerns a drug the patient did receive and brought back. Only the former is generally lawful.
4. Narrow Reuse Exceptions: Sealed Unit-Dose & Donation/Repository Programs
Where state law allows reuse at all, NABP and most states require strict conditions, including that the returned product be in tamper-evident, bulk, unit-of-use, or unit-dose packaging that remains in the dispensing pharmacy's original packaging with intact labeling and expiration dating—typically arising when a licensed facility (such as a long-term-care pharmacy) returns sealed unit-dose medications that were never administered. Such programs usually require prior approval from the state board of pharmacy , which may demand proof that the returned product is safe for redispensing.
State prescription drug donation/repository programs (for example, Iowa's Prescription Drug Donation Repository, established 2005) authorize medical facilities and pharmacies to redispense qualifying donated drugs to low-income patients . Common features:
- Donations limited to sealed, unopened, non-controlled drugs within their expiration dating;
- Controlled substances are universally prohibited from donation and repository programs;
- The receiving program inspects, stores, and documents donated drugs under board-approved criteria;
Donations often originate from long-term-care providers returning sealed unit-dose stock or from physician-office samples where state law permits sample donation.
5. MPJE Reasoning Pattern
Determine whether the drug ever left the pharmacy (restocking versus patient return).
If it is a controlled substance that was dispensed, the answer is no redispensing —route it to disposal via an authorized collector or reverse distributor.
If it is a non-controlled patient return, the default is no redispensing unless a specific state exception (sealed unit-dose, board-approved program, or repository) applies.
If the prescription was never picked up , restocking with billing reversal and documentation is the lawful path.
Always distinguish disposal-only take-back (no reuse, no credit) from reuse exceptions (narrow and state-authorized).
Bottom line: Patient-returned dispensed drugs are presumptively not redispensable; controlled substances are never redispensable; restocking applies only to never-dispensed fills; and reuse or repository programs are rare, state-authorized, and exclude controlled substances.